Skip to content
Adam Torkildson – Lifestyle
Author:
Dasher Neuroscience Holdings Inc.
Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
July 28, 2026